Uterine sarcomas: A review

Gynecologic Oncology

Volumn 116, Issue 1, 2010, Pages 131-139

  D'Angelo, Emanuela ^a   Prat, Jaime ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Adenosarcoma; Carcinosarcoma; Endometrial stromal sarcoma; Leiomyosarcoma; Undifferentiated endometrial sarcoma; Uterine sarcomas

Indexed keywords

KI 67 ANTIGEN; ONCOPROTEIN; PROTEIN P16; PROTEIN P53;

ADENOSARCOMA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SURVIVAL; CARCINOSARCOMA; ENDOMETRIUM SARCOMA; FIBROMA; HUMAN; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; UTERUS SARCOMA; WORLD HEALTH ORGANIZATION;

ADENOSARCOMA; CARCINOSARCOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; NEOPLASM STAGING; SARCOMA; SARCOMA, ENDOMETRIAL STROMAL; UTERINE NEOPLASMS;

EID: 70749135317     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.09.023     Document Type: Review

References (74)

1. Major F.J., Blessing J.A., Silverberg S.G., et al. Prognostic factors in early stage uterine sarcoma: a Gynecologic Oncology Group study. Cancer 71 (1993) 1702-1709
2. Giuntoli II R.L., Metzinger D.S., DiMarco C.S., Cha S.S., Sloan J.A., Keeney G.L., et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol. Oncol. 89 (2003) 460-469
3. World Health Organization classification of tumours. In: Tavassoli F.A., and Devilee P. (Eds). Pathology and genetics of tumours of the breast and female genital organs (2003), IARC Press, Lyon
4. FIGO staging for uterine sarcomas. Int. J. Gynaecol. Obstet. 104 (2009) 179
5. Perri T., Korach J., Sadetzki S., Oberman B., Fridman E., and Ben-Baruch G. Uterine leiomyosarcoma: does the primary surgical procedure matter. Int. J. Gynecol. Cancer 19 (2009) 257-260
6. Zaloudek C.J., and Norris H.J. Mesenchymal tumors of the uterus. In: Fenoglio C.M., and Wolff M. (Eds). Progress in Surgical Pathology Vol. III (1981), Masson-Publishing Inc., New York 1-35
7. Evans H.L., Chawla S.P., Simpson C., and Finn K.P. Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases with emphasis on diagnostic criteria and prognostic factors. Cancer 62 (1988) 2239-2247
8. Perrone T., and Dehner L.P. Prognostically favorable "mitotically active" smooth-muscle tumors of the uterus. A clinicopathologic study of 10 cases. Am. J. Surg. Pathol. 12 (1988) 1-8
9. Kurman R.J., and Norris H.J. Mesenchymal tumors of the uterus. VI. Epithelioid smooth muscle tumors including leiomyoblastoma and clear-cell leiomyoma. A clinical and pathological analysis of 26 cases. Cancer 37 (1976) 1853-1865
10. Atkins K., Bell S., Kempson M., and Hendrickson M. Myxoid smooth muscle tumors of the uterus. Modern Pathol. 132A (2001) 14
11. Abeler V.M., Royne O., Thoresen S., Danielsen H.E., Nesland J.M., and Kristensen G.B. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 54 (2009) 355-364
12. Mayerhofer K., Obermair A., Windbichler G., et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol. Oncol. 74 (1999) 196-201
13. Atkins K.A., Arronte N., Darus C.J., and Rice L.W. The use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. Am. J. Surg. Pathol. 32 (2008) 98-102
14. Bodner-Adler B., Bodner K., Czerwenka K., Kimberger O., Leodolter S., et al. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol. Oncol. 96 (2005) 62-66
15. Chen L., and Yang B. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int. J. Gynecol. Pathol. 27 (2008) 326-332
16. Mittal K., and Demopoulos R.I. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum. Pathol. 32 (2001) 984-987
17. O'Neill C.J., McBride H.A., Connolly L.E., and McCluggage W.G. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology 50 (2007) 851-858
18. Jeffers M.D., Farquharson M.A., Richmond J.A., and McNicol A.M. P53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus. J. Pathol. 177 (1995) 65-70
19. Akhan S.E., Yavuz E., Tecer A., et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol. Oncol. 99 (2005) 36-42
20. Raspollini M.R., Pinzani P., Simi L., Amunni G., Villanucci A., et al. Uterine leiomyosarcomas express KIT protein but lack mutation(s) in exon 9 of c-KIT. Gynecol. Oncol. 98 (2005) 334-335
21. Lehtonen H.J., Kiuru M., Ylisaukko-Oja S.K., Salovaara R., Herva R., et al. Increased risk of cancer in patients with fumarate hydratase germline mutation. J. Med. Genet. 43 (2006) 523-526
22. Ylisaukko-oja S.K., Kiuru M., Lehtonen H.J., Lehtonen R., Pukkala E., et al. Analysis of fumarate hydratase mutations in a population-based series of early onset uterine leiomyosarcoma patients. Int. J. Cancer 119 (2006) 283-287
23. D'Angelo E., Spagnoli L.G., and Prat J. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. Hum. Pathol. 40 (2009) 1571-1585
24. Koivisto-Korander R., Butzow R., Koivisto A.M., and Leminen A. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001. Gynecol. Oncol. 111 (2008) 74-81
25. Wang W.L., Soslow R.A., Hensley M., et al. Histopathologic prognostic factors in stage I uterine leiomyosarcomas (Ut-LMS): a clinicopathologic study of 28 cases. Mod. Path. (2007) 217A
26. Denschlag D., Masoud I., Stanimir G., and Gilbert L. Prognostic factors and outcome in women with uterine sarcoma. Eur. J. Surg. Oncol. 33 (2007) 91-95
27. Jones M.W., and Norris H.J. Clinicopathologic study of 28 uterine leiomyosarcomas with metastasis. Int. J. Gynecol. Pathol. 14 (1995) 243-249
28. Larson B., Silfversward C., Nilsson B., and Petterson F. Prognostic factors in uterine leiomyosarcoma: a clinicopathologic study of 143 cases. The Radiumhemmet series, 1936-1981. Acta. Oncol. 29 (1990) 185-191
29. Nordal R., Kristensen G.B., Kaern J., Stenwig A.E., Pettersen E.O., and Trope C.G. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta. Oncol. 34 (1995) 797-802
30. Kapp D.S., Shin J.Y., and Chan J.K. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 112 (2008) 820-830
31. Hensley M.L., Blessing J.A., Mannel R., and Rose P.G. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol. Oncol. 109 (2008) 329-334
32. Hensley M.L., Ishill N., Soslow R., Larkin J., Abu-Rustum N., Sabbatini P., et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol. Oncol. 112 (2009) 563-567
33. Hardman M.P., Roman J.J., Burnett A.F., and Santin A.D. Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet. Gynecol. 110 (2007) 518-520
34. Bell S.W., Kempson R.L., and Hendrickson M.R. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am. J. Surg. Pathol. 18 (1994) 535-558
35. Ip P.P., Cheung A.N., and Clement P.B. Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMP): a clinicopathologic analysis of 16 cases. Am. J. Surg. Pathol. 33 (2009) 992-1005
36. Guntupalli S.R., Ramirez P.T., Anderson M.L., Milam M.R., Bodurka D.C., and Malpica A. Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis. Gynecol. Oncol. 113 (2009) 324-326
37. Baker P., and Oliva E. Endometrial stromal tumours of the uterus: a practical approach using conventional morphology and ancillary techniques. J. Clin. Pathol. 60 (2007) 235-243
38. Dionigi A., Oliva E., Clement P.B., and Young R.H. Endometrial stromal nodules and endometrial stromal tumors with limited infiltration: a clinicopathologic study of 50 cases. Am. J. Surg. Pathol. 26 (2002) 567-581
39. Tavassoli F.A., and Norris H.J. Mesenchymal tumours of the uterus. VII. A clinicopathological study of 60 endometrial stromal nodules. Histopathology 5 (1981) 1-10
40. Schilder J.M., Hurd W.W., Roth L.M., and Sutton G.P. Hormonal treatment of an endometrial stromal nodule followed by local excision. Obstet. Gynecol. 93 (1999) 805-807
41. Chang K.L., Crabtree G.S., Lim-Tan S.K., Kempson R.L., and Hendrickson M.R. Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am. J. Surg. Pathol. 14 (1990) 415-438
42. McCluggage W.G., Sumathi V.P., and Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 39 (2001) 273-278
43. Chu P.G., Arber D.A., Weiss L.M., and Chang K.L. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod. Pathol. 14 (2001) 465-471
44. Oliva E., Young R.H., Amin M.B., and Clement P.B. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am. J. Surg. Pathol. 26 (2002) 403-412
45. de Leval L., Waltregny D., Boniver J., Young R.H., Castronovo V., and Oliva E. Use of histone deacetylase 8 (HDAC8), a new marker of smooth muscle differentiation, in the classification of mesenchymal tumors of the uterus. Am. J. Surg. Pathol. 30 (2006) 319-327
46. Irving J.A., Carinelli S., and Prat J. Uterine tumors resembling ovarian sex cord tumors are polyphenotypic neoplasms with true sex cord differentiation. Mod. Path. 19 (2006) 17-24
47. Reich O., Regauer S., Urdl W., Lahousen M., and Winter R. Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas. Br. J. Cancer 82 (2000) 1030-1034
48. Nucci M.R., Harburger D., Koontz J., Dal Cin P., and Sklar J. Molecular analysis of the JAZF1-JJAZ1 gene fusion by RT-PCR and fluorescence in situ hybridization in endometrial stromal neoplasms. Am. J. Surg. Pathol. 31 (2007) 65-70
49. Bodner K., Bodner-Adler B., Obermair A., Windbichler G., Petru E., Mayerhofer S., et al. Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients. Gynecol. Oncol. 81 (2001) 160-165
50. Chan J.K., Kawar N.M., Shin J.Y., Osann K., Chen L.M., Powell C.B., et al. Endometrial stromal sarcoma: a population-based analysis. Br. J. Cancer 99 (2008) 1210-1215 electronic publication 2008 Sep 23
51. Blom R., Malmström H., and Guerrieri C. Endometrial stromal sarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 17 cases. Int. J. Gynecol. Cancer 9 (1999) 98-104
52. Haberal A., Kayikçioǧlu F., Boran N., Calişkan E., Ozgül N., and Köse M.F. Endometrial stromal sarcoma of the uterus: analysis of 25 patients. Eur. J. Obstet. Gynecol. Reprod. Biol. 109 (2003) 209-213
53. Spano J.P., Soria J.C., Kambouchner M., Piperno-Neuman S., Morin F., Morere J.F., et al. Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Med. Oncol. 20 (2003) 87-93
54. Shah J.P., Bryant C.S., Kumar S., Ali-Fehmi R., Malone Jr. J.M., and Morris R.T. Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet. Gynecol. 112 (2008) 1102-1108
55. Li A.J., Giuntoli II R.L., Drake R., Byun S.Y., Rojas F., Barbuto D., et al. Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet. Gynecol. 106 (2005) 1304-1308
56. Chu M.C., Mor G., Lim C., Zheng W., Parkash V., and Schwartz P.E. Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol. Oncol. 90 (2003) 170-176
57. Amant F., De Knijf A., Van Calster B., Leunen K., Neven P., Berteloot P., et al. Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. Br. J. Cancer 97 (2007) 1194-1199
58. Weitmann H.D., Kucera H., Knocke T.H., and Pötter R. Surgery and adjuvant radiation therapy of endometrial stromal sarcoma. Wien Klin Wochenschr 114 (2002) 44-49
59. Kurihara S., Oda Y., Ohishi Y., Iwasa A., Takahira T., Kaneki E., et al. Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. Am. J. Surg. Pathol. 32 (2008) 1228-1238
60. Mansi J.L., Ramachandra S., Wiltshaw E., and Fisher C. Endometrial stromal sarcomas. Gynecol. Oncol. 36 (1990) 113-118
61. Sutton G., Blessing J.A., Park R., DiSaia P.J., and Rosenshein N. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. Obstet. Gynecol. 87 (1996) 747-750
62. Clement P.B., and Scully R.E. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum. Pathol. 21 (1990) 363-381
63. Gallardo A., and Prat J. Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am. J. Surg. Pathol. 33 (2009) 278-288
64. Soslow R.A., Ali A., and Oliva E. Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases. Am. J. Surg. Pathol. 32 (2008) 1013-1021
65. Blom R., and Guerrieri C. Adenosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53 and mdm-2 analysis of 11 cases. Int. J. Gynecol. Cancer 9 (1999) 37-43
66. Ferguson S.E., Tornos C., Hummer A., Barakat R.R., and Soslow R.A. Prognostic features of surgical stage I uterine carcinosarcoma. Am. J. Surg. Pathol. 31 (2007) 1653-1661
67. Silverberg S.G., Major F.J., Blessing J.A., Fetter B., Askin F.B., Liao S.Y., et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int. J. Gynecol. Pathol. 9 (1990) 1-19
68. Yamada S.D., Burger R.A., Brewster W.R., Anton D., Kohler M.F., and Monk B.J. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 15 88 (2000) 2782-2786
69. George E., Lillemoe T.J., Twiggs L.B., and Perrone T. Malignant mixed mullerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival. Int. J. Gynecol. Pathol. 14 (1995) 39-44
70. Soslow R.A., Bissonnette J.P., Wilton A., Ferguson S.E., Alektiar K.M., Duska L.R., et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am. J. Surg. Pathol. 31 (2007) 979-987
71. Alektiar K.M., McKee A., Lin O., et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 79-85
72. Callister M., Ramondetta L.M., Jhingran A., Burke T.W., and Eifel P.J. Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 786-796
73. Livi L., Paiar F., Shah N., Blake P., Villanucci A., Amunni G., et al. Uterine sarcoma: twenty-seven years of experience. Int. J. Radiat. Oncol. Biol. Phys. 57 (2003) 1366-1373
74. Villena-Heinsen C., Diesing D., Fischer D., Griesinger G., Maas N., Diedrich K., et al. Carcinosarcomas-a retrospective analysis of 21 patients. Anticancer Res. 26 (2006) 4817-4823